Nuvalent Announces Public Offering of Common Stock
Nuvalent Announces Public Offering of Common Stock Nuvalent Announces Public Offering of Common Stock PR Newswire CAMBRIDGE, Mass., Nov. 17, 2025 CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire...
PR Newswire·2h ago
More News
Nuvalent Shares Jump 14% After Positive Pivotal ALKOVE-1 Trial Results In ALK-Positive NSCLC
(RTTNews) - Nuvalent, Inc. (NUVL) surged 14.24% to $110.24, up $13.74, following an announcement of strong topline data from its pivotal ALKOVE-1 trial evaluating neladalkib (NVL-655) in...
Nasdaq News: Markets·3h ago
Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer
Nuvalent reports durable neladalkib responses in pretreated and TKI-na ve ALK-positive NSCLC, with strong rates in the ALKOVE-1 trial.read more...
Benzinga·5h ago
Why Did Nuvalent Stock Surge 15% Today?
The company announced strong topline results from its ALKOVE-1 Phase 1/2 trial, evaluating its investigational drug Neladalkib.
Stocktwits·5h ago
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC Nuvalent Announces Positive Topline Pivotal...
PR Newswire·11h ago
Candriam S.C.A. Sells 52,870 Shares of Nuvalent, Inc. $NUVL
Candriam S.C.A. lessened its holdings in shares of Nuvalent, Inc. (NASDAQ:NUVL - Free Report) by 14.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·3d ago
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib
Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib Nuvalent Announces Timing of Topline Pivotal...
PR Newswire·3d ago
Nuvalent (NASDAQ:NUVL) Now Covered by Canaccord Genuity Group
Canaccord Genuity Group started coverage on Nuvalent in a report on Wednesday. They set a "buy" rating and a $126.00 price target for the company...
MarketBeat·4d ago
Nuvalent (NASDAQ:NUVL) Releases Earnings Results, Misses Expectations By $0.32 EPS
Nuvalent (NASDAQ:NUVL - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.38) by...
MarketBeat·5d ago
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Recommendation of "Moderate Buy" from Analysts
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. One...